hotspot -WSS

hotspot

author：entertainment 2025-09-30 14:10:08 - browse：6

Photo of an arrangement of aspirin pills — Patrick Sison/AP

Low-dose aspirin led to a reduction in liver fat among patients with metabolic-associated liver disease, a small study out of Boston found.

The clinical trial, led by Tracey Simon of Massachusetts General Hospital and Harvard Medical School, compared two groups of patients with metabolic dysfunction-associated steatotic liver disease, or MASLD. One group was given baby aspirin daily for six months, while the other received a placebo pill. At the end of the study period, the aspirin group had reduced hepatic fat content while the placebo group had higher fat buildup.

MASLD (formerly known as non-alcoholic fatty liver disease) is a growing health threat, with 1 in 3 Americans having a troublesome amount of fat in their liver. The lipid buildup feeds into a toxic cycle of inflammation, tissue damage and, ultimately, irreversible scarring.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： TytoCare raises $49 million to build out AI

WSS

STAT Boddities: What happens to the brain when we get scared?

Tome Biosciences co

Microsoft strikes partnership with Duke Health to advance health AI

White House drug shortage group privately met with industry

Congress might make insulin pumps more accessible to the blind

Latigo launches with $135 million for Vertex

hotspot

hotspot

hotspot

At least 13 dead in Texas as scorching temps continue

Juul documents reveal insider tactics on political lobbying

DIEP, the 'gold standard' of breast reconstruction, is under threat

Juul documents reveal insider tactics on political lobbying

Alkermes shareholders re

Verily hires former Apple Health leader as chief scientific officer

BioMarin wins approval for gene therapy to treat hemophilia A

Microsoft strikes partnership with Duke Health to advance health AI

Medicare details structure of new drug price negotiation program

Verily hires former Apple Health leader as chief scientific officer

focus

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Verily hires former Apple Health leader as chief scientific officer

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Congress considering partial increase for doctor pay in Medicare

'Ancient DNA,' 23andMe reveal African American ancestries

focus

explore

focus

hotspot